RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of serious human diseases. The company has developed novel and proprietary nanotransporters that have been shown to deliver RNAi compounds to target tissues in animal models.
Senova Systems owns an exclusive worldwide license from Oxford University for a breakthrough pH sensor that does not require calibration, is not subject to fouling, and does not drift with changes in temperature. The company is developing these revolutionary new pH Meters to meet specific needs in all process industries.
Develops, manufactures, and sells a broad range of biological based materials and services essential for the manufacture of diagnostic tests, commercial bioproduction of therapeutic drugs,including clinically annotated DNA and RNA.
Sirnaomics, Inc. is dedicated to becoming the leader in the RNAi technology focusing on (1) enhancement of the potency of active pharmaceutical ingredient (API) using multi-targeted small interfering RNA (siRNA) cocktail; (2) improvement of the API delivery in vivo using clinical viable synthetic polymeric and lipid nanoparticles.
SurModics® Synthetic ECM is a synthetic, stable, and scalable cell culture platform that provides an in vivo-like cell culture environment with its biomimetic extracellular matrix structure and surface. The technology produces results for cell research and cell-related applications. The nanofibrillar matrix utilizes Ultra-Web™ technology.
T2 Biosystems is creating a new generation of lab-quality diagnostic tools. Its technology is based on superparamagnetic nanoparticles. NanoDx particles have a superparamagnetic metal core surrounded by a polymer layer decorated by multiple analyte-specific binding agents. This nanoparticle platform can be used with a variety of binding agents such as antibodies, nucleic acids and small molecules.
Tempo is focused on significantly improving the efficacy and safety profile of existing and new drugs employing advances in nanotechnology. The Company utilizes its proprietary Nanocell™ technology to develop multi-compartmental, nanoparticle-based therapeutics in which two drugs with varied release rates are packaged within a single nanoparticle.
The company has leveraged its experience with magnetic nanomaterials and magnetic field energy to make antibodies tumoricidal and more therapeutically selective, without the side effects of conventional therapies.
Developed and manufactures a novel, biomaterial which utilizes hydrogel nanoparticles which aggregate to form a material of varying strength and elasticity which has extensive medical application including wound management and burn care, tissue regeneration and drug delivery devices.
The company is developing Drug-Coated Balloons (DCB) that are designed to be a more precise delivery vehicle and be the standard treatment of choice for vascular atherosclerosis as well as non-vascular applications.
WaferGen Biosystems, Inc. is a leader in the development, manufacture and commercialization of next-generation systems for gene expression, genotyping, stem cell research and cell biology for the life science and pharmaceutical industries.
WaveSense develops, manufactures, and markets breakthrough analytical nanotechnologies for use in cellular and molecular assay markets. The company's patented and hierarchy technology is called Xenographic Retention Chromatography (XRC) - branded as EpiSep, which is a lateral flow separations platform that provides rapid, advanced detection and characterization of live cells, proteins, and/or genes. Researchers can then harvest the targets for interrogation purposes within their desired application.